MIRA Pharmaceuticals (NASDAQ:MIRA) | WebDisclosure

Basculer en Français

10817	Companies
234452	Keywords
163309	Articles
125451	Press releases

Home
Companies
MIRA Pharmaceuticals

PRESS RELEASE

published on 08/19/2025 at 14:30, 11 months 22 days ago

MIRA Pharmaceuticals Announces Completion of Phase 1 Single Ascending Dose for Oral Ketamir-2 with No Safety Concerns, Advances to Multiple Ascending Dose Stage
MIRA Pharmaceuticals, Inc. announces successful completion of Phase 1 Single Ascending Dose trial for oral Ketamir-2, preparing for U.S. Phase 2a trial in Q4 2025

Clinical Trial Phase 1 MIRA Pharmaceuticals Ketamir-2 Neuropathic Pain
BRIEF

published on 08/12/2025 at 14:35, 11 months 29 days ago

MIRA Pharmaceuticals développe le kétamir-2 pour le traitement de la douleur neuropathique

Essais Cliniques Croissance Du Marché Médicaments Ketamir-2 Douleur Neuropathique
BRIEF

published on 08/12/2025 at 14:35, 11 months 29 days ago

MIRA Pharmaceuticals Advances Ketamir-2 for Neuropathic Pain Treatment

Pharmaceuticals Clinical Trials Market Growth Ketamir-2 Neuropathic Pain
PRESS RELEASE

published on 08/12/2025 at 14:30, 11 months 29 days ago

MIRA Pharmaceuticals' Second Ketamir-2 Manuscript Accepted for Peer-Reviewed Publication Demonstrating Superior Efficacy in Preclinical Neuropathic Pain Models Versus Ketamine, Gabapentin, or Pregabalin
MIRA Pharmaceuticals announces the acceptance of a manuscript in Frontiers in Pharmacology detailing Ketamir-2's efficacy in neuropathic pain, supporting Phase 2a trials by 2025

Clinical Trials MIRA Pharmaceuticals Ketamir-2 Neuropathic Pain Pharmacology
BRIEF

published on 07/30/2025 at 13:35, 1 year ago

Le kétamir-2 topique de MIRA Pharmaceuticals est comparable à la morphine injectée dans une étude sur la douleur

Soulagement De La Douleur Étude Préclinique Kétamir-2 Topique Comparaison De La Morphine Traitement Localisé
BRIEF

published on 07/30/2025 at 13:35, 1 year ago

MIRA Pharmaceuticals' Topical Ketamir-2 Matches Injected Morphine in Pain Study

Preclinical Study Pain Relief Topical Ketamir-2 Morphine Comparison Localized Treatment
PRESS RELEASE

published on 07/30/2025 at 13:30, 1 year ago

MIRA Pharmaceuticals Reports New Topical Ketamir-2 shows comparable effects to Injected Morphine in Preclinical Pain Study
MIRA Pharmaceuticals announces new preclinical data showing topical Ketamir-2 provides effective pain relief comparable to injected morphine in animal models. The treatment has potential for both centralized and localized pain pathways

Preclinical Data MIRA Pharmaceuticals Ketamir-2 Neuropathic Pain Topical Pain Relief
BRIEF

published on 07/29/2025 at 13:35, 1 year ago

MIRA Pharmaceuticals reçoit le feu vert de la FDA pour les essais du kétamir-2

Autorisation De La FDA Expansion Stratégique Ketamir-2 Douleur Neuropathique Essai De Phase 1
BRIEF

published on 07/29/2025 at 13:35, 1 year ago

MIRA Pharmaceuticals Receives FDA Green Light for Ketamir-2 Trials

FDA Clearance Phase 1 Trial Strategic Expansion Ketamir-2 Neuropathic Pain
PRESS RELEASE

published on 07/29/2025 at 13:30, 1 year ago

MIRA Pharmaceuticals Announces FDA Clearance of IND for Ketamir-2, Enabling U.S. Clinical Trials in Neuropathic Pain
MIRA Pharmaceuticals advances non-opioid oral drug Ketamir-2 for neuropathic pain, clears FDA IND for Phase 2a, demonstrates potent effects in preclinical studies

FDA Preclinical Studies MIRA Pharmaceuticals Ketamir-2 Neuropathic Pain

Accesswire

Published on 08/11/2026 at 07:00, 54 minutes ago

Alaska Energy Metals Announces Closing of Shares for Debt Settlement
Published on 08/11/2026 at 00:40, 7 hours 14 minutes ago

CORRECTION FROM SOURCE: Fermi Announces Binding Lease Agreement with TensorWave
Published on 08/11/2026 at 00:25, 7 hours 29 minutes ago

Empress Reports 2026 Second Quarter Financial Results
Published on 08/10/2026 at 23:35, 8 hours 19 minutes ago

NioCorp Project to Expand Production to 8 Made-in-USA Critical Minerals Over a 40-Year Mine Life with an Estimated $4.1 Billion Pre-Tax NPV8%
Published on 08/10/2026 at 23:30, 8 hours 24 minutes ago

Condor and Element79 Agree on Restructured Terms for Lucero Project

View all ACCESSWIRE

EQS Group

Published on 08/11/2026 at 07:42, 11 minutes ago

LAIQON AG: Strong revenue growth in the first half of 2026; increase in EBITDA in Q2 2026 by EUR 2.45 million to EUR +1.08 million
Published on 08/11/2026 at 07:30, 24 minutes ago

STS Group AG's first half of 2026 lays a strong foundation for meeting its full-year targets
Published on 08/11/2026 at 07:30, 24 minutes ago

Dermapharm Holding SE reports profitable growth in H1 2026 and confirms guidance
Published on 08/11/2026 at 07:30, 24 minutes ago

Salzgitter Group reports encouraging first half of 2026
Published on 08/11/2026 at 07:01, 53 minutes ago

NORMA Group delivers significantly higher profitability in the second quarter of 2026; Industry Applications continues to grow

Les Echos

Published on 08/10/2026 at 18:00, 13 hours 54 minutes ago

AXA: Information relating to the number of voting rights and shares making up the share capital on 31/07/2026
Published on 08/10/2026 at 18:00, 13 hours 54 minutes ago

AXA : Information relative au nombre total de droits de vote et d'actions composant le capital social au 31/07/2026
Published on 08/10/2026 at 17:45, 14 hours 9 minutes ago

Weekly share buyback
Published on 08/10/2026 at 17:45, 14 hours 9 minutes ago

Déclaration hebdomadaire de rachat d'actions
Published on 08/10/2026 at 11:53, 20 hours ago

GUILLEMOT CORPORATION | Information regarding the total number of voting rights and shares 31/07/2026

View all LES ECHOS COMFI WIRE